Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type# f: m* q9 R1 a
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
" U* D3 }# V" l4 M' B" _) K+ Author Affiliations& w- d, U* Q/ e( w* I- V9 }
. e) U: E0 o; E; j& F8 U4 {1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan ; T6 b) U0 K& F: \
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
( o% B2 S8 I& u# K3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ! H9 j: u( K# E/ p' g' b4 q
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan & L7 m; P( G# [4 Y4 k9 z, g: ]! o
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
/ r9 D3 m$ L" b- e& ]' v: c, W6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan , F4 b& g. y# w* Q7 X
7Kinki University School of Medicine, Osaka 589-8511, Japan
' {$ Y ^; c6 K. r' G8Izumi Municipal Hospital, Osaka 594-0071, Japan
2 A6 A& {2 E0 v0 v9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
$ a; Z* L( y4 E9 o. rCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp ' v) F# C( f" C M! Q5 E
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
9 D' N5 R+ G ^0 p7 E' A
+ ]' g) f, q+ ], n |